These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 22755160)

  • 1. [Gamma-secretase inhibitors and modulators].
    Iwai A
    Nihon Rinsho; 2011 Dec; 69 Suppl 10 Pt 2():83-7. PubMed ID: 22755160
    [No Abstract]   [Full Text] [Related]  

  • 2. What the halted phase III γ-secretase inhibitor trial may (or may not) be telling us.
    Schor NF
    Ann Neurol; 2011 Feb; 69(2):237-9. PubMed ID: 21387368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lessons from a failed γ-secretase Alzheimer trial.
    De Strooper B
    Cell; 2014 Nov; 159(4):721-6. PubMed ID: 25417150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. γ-Secretase modulator in Alzheimer's disease: shifting the end.
    Xia W; Wong ST; Hanlon E; Morin P
    J Alzheimers Dis; 2012; 31(4):685-96. PubMed ID: 22710916
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecule of the month. Semagacestat.
    Drug News Perspect; 2008 Sep; 21(7):390. PubMed ID: 19259551
    [No Abstract]   [Full Text] [Related]  

  • 6. Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease.
    Siemers ER; Quinn JF; Kaye J; Farlow MR; Porsteinsson A; Tariot P; Zoulnouni P; Galvin JE; Holtzman DM; Knopman DS; Satterwhite J; Gonzales C; Dean RA; May PC
    Neurology; 2006 Feb; 66(4):602-4. PubMed ID: 16505324
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Exacerbation of psoriasiform lesions by a gamma-secretase inhibitor].
    Trechot P; Schmutz JL
    Ann Dermatol Venereol; 2013 Oct; 140(10):669-70. PubMed ID: 24090904
    [No Abstract]   [Full Text] [Related]  

  • 8. Learning by failing: ideas and concepts to tackle γ-secretases in Alzheimer's disease and beyond.
    De Strooper B; Chávez Gutiérrez L
    Annu Rev Pharmacol Toxicol; 2015; 55():419-37. PubMed ID: 25292430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in the identification of γ-secretase inhibitors for the treatment of Alzheimer's disease.
    D'Onofrio G; Panza F; Frisardi V; Solfrizzi V; Imbimbo BP; Paroni G; Cascavilla L; Seripa D; Pilotto A
    Expert Opin Drug Discov; 2012 Jan; 7(1):19-37. PubMed ID: 22468891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. What can be inferred from the interruption of the semagacestat trial for treatment of Alzheimer's disease?
    Cummings J
    Biol Psychiatry; 2010 Nov; 68(10):876-8. PubMed ID: 21035622
    [No Abstract]   [Full Text] [Related]  

  • 11. Exacerbation of psoriatic skin lesions in a patient with Alzheimer disease receiving gamma-secretase inhibitor.
    Hsu CK; Hsu CC; Lee JY; Kuo YM; Pai MC
    J Am Acad Dermatol; 2013 Feb; 68(2):e46-8. PubMed ID: 23317986
    [No Abstract]   [Full Text] [Related]  

  • 12. Hidradenitis Suppurativa-Like Lesions Associated with Pharmacologic Inhibition of Gamma-Secretase.
    O'Sullivan Coyne G; Woodring TS; Lee CR; Chen AP; Kong HH
    J Invest Dermatol; 2018 Apr; 138(4):979-981. PubMed ID: 29138057
    [No Abstract]   [Full Text] [Related]  

  • 13. NerveCenter: Phase III Alzheimer trial halted: Search for therapeutic biomarkers continues.
    Samson K
    Ann Neurol; 2010 Oct; 68(4):A9-A12. PubMed ID: 20976761
    [No Abstract]   [Full Text] [Related]  

  • 14. Semagacestat for treatment of Alzheimer's disease.
    Doody RS; Aisen PS; Iwatsubo T
    N Engl J Med; 2013 Oct; 369(17):1661. PubMed ID: 24152267
    [No Abstract]   [Full Text] [Related]  

  • 15. Semagacestat for treatment of Alzheimer's disease.
    Gupta VB; Gupta VK; Martins R
    N Engl J Med; 2013 Oct; 369(17):1660-1. PubMed ID: 24152268
    [No Abstract]   [Full Text] [Related]  

  • 16. Semagacestat for treatment of Alzheimer's disease.
    Pomara N
    N Engl J Med; 2013 Oct; 369(17):1661. PubMed ID: 24152269
    [No Abstract]   [Full Text] [Related]  

  • 17. New pathway links γ-secretase to inflammation and memory while sparing notch.
    Gandy S; Wustman B
    Ann Neurol; 2011 Jan; 69(1):5-7. PubMed ID: 21280069
    [No Abstract]   [Full Text] [Related]  

  • 18. A canine model to evaluate efficacy and safety of γ-secretase inhibitors and modulators.
    Borghys H; Tuefferd M; Van Broeck B; Clessens E; Dillen L; Cools W; Vinken P; Straetemans R; De Ridder F; Gijsen H; Mercken M
    J Alzheimers Dis; 2012; 28(4):809-22. PubMed ID: 22072214
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Progress in the development of anti-amyloid drugs for treatment of Alzheimer's disease.].
    Shitaka Y; Mitani Y; Nagakura A; Miyake A; Matsuoka N
    Nihon Yakurigaku Zasshi; 2010 Jul; 136(1):15-20. PubMed ID: 20628208
    [No Abstract]   [Full Text] [Related]  

  • 20. Semagacestat, a gamma-secretase inhibitor for the potential treatment of Alzheimer's disease.
    Imbimbo BP; Peretto I
    Curr Opin Investig Drugs; 2009 Jul; 10(7):721-30. PubMed ID: 19579178
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.